Royal Olympic Hotel
Athens, 15-16/3/2019

IASIS PHARMA participated as a Golden Sponsor in the 24th Greek Conference for Helicobacter pylori and Other Infections of the Digestive Tract. The conference was organized by the Greek Society of Gastroenterology and the Hellenic Society for Infectious Diseases, and took place at Royal Olympic Hotel Athens, 15-16 March 2019.

IASIS PHARMA active participation was further strengthened with mastihatherapy® caps, the unique traditional herbal medicinal product containing 350mg of pure Chios Mastic (pistacia lentiscus), recommended for the treatment of functional dyspepsia. Medical experts were especially interested about this recognized herbal medicinal product (EMA, 2015), known to humanity for over 2.500 years with several historical reports, but also many scientific studies that are still being carried out. One of the most recent study is the “Development and application of HPLC-DAD and HPTLC methods for quality control of Chios Mastic and Products”.

It is worth to mention that all the event’s participants had the chance to be informed about both IASIS PHARMA participation to Chios Mastiha Research and Development Center (Kallimasia, isle of Chios, Greece) and IASIS PHARMA brand new, state-of-the-art Manufacturing Facilities, Distribution Center and R&D Center.

During the Conference, a round table discussion was organized by IASIS PHARMA, under the title “Chios Mastic, the Newest Data”, which gathered the interest of many health professionals who attended lectures carried out from special speakers with subjects such as:

– Systematic pharmacological study of Chios Mastic during the last decade, from the Pharmacognosy – Pharmaceutical Lab of the National and Kapodistrian University of Athens (UOA).
(speaker: S. Mitakou, Pharmacist, Professor of the Pharmacognosy – Chemistry department of the UOA).

– Biological evaluation of Chios Mastic in cellular and in vivo experimental models (speaker: I. Trougakos, Biology Professor of the UOA).

– Chios Mastic: from chemical designation of its active substances to clinical application.
(speaker: V. Pachi, Chemist MSc, doctoral candidate for the Pharmaceutical department of the UOA).